Abstract
Despite the excellent prognosis for patients with newly diagnosed Down syndrome–associated acute megakaryoblastic leukemia (DS-AMKL), patients with relapsed DS-AMKL have very poor prognosis, and there is no standard treatment for such patients. We report a case of a child with relapsed DS-AMKL who was cured with non-myeloablative chemotherapy. A 19-month-old boy with Down syndrome, who had transient leukemia as a newborn, developed DS-AMKL (positive for GATA1 mutation), after a brief phase of myelodysplastic syndrome. He was treated with cytarabine, daunorubicin, oral thioguanine, and intrathecal cytarabine for induction; and high-dose cytarabine plus L-asparaginase and intrathecal cytarabine for intensification and consolidation. He exhibited remission but relapsed within 6 weeks after the completion of therapy. A second remission was achieved with high-dose cytarabine plus mitoxantrone (HAM), after which he received 4 more cycles of chemotherapy: 1 course of HAM; 1 course of high-dose cytarabine; and 2 courses of cytarabine, fludarabine, and granulocyte colony-stimulating factor. He has been disease-free for 65 months after the completion of chemotherapy. His bone marrow aspirate became negative for GATA1 mutation after the fourth cycle of chemotherapy, and he has remained negative at 5, 7, and 8 months after completion of therapy. A non-myeloablative chemotherapy regimen with high-dose cytarabine, mitoxantrone, and fludarabine could be curative for children with DS-AMKL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.